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Purpose: To compare radiologic response as defined according to
both Response Evaluation Criteria in Solid Tumors
(RECIST) and the new Choi criteria recently proposed for
gastrointestinal stromal tumors with pathologic response in
high-grade soft-tissue sarcomas (STSs) treated with preoper-
ative chemotherapy and radiation therapy.
Materials and
Methods:
The institutional ethical committee approved the trial in
which patients were enrolled. Signed informed consent was
obtained. Thirty-seven patients (21 men, 16 women; mean
age, 44.2 years) enrolled in a collaborative randomized trial
on preoperative chemotherapy and radiation therapy in lo-
calized high-risk STS at a single institution were selected for
this retrospective analysis. Tumor response to preoperative
treatment was assessed by using both RECIST and Choi
criteria at computed tomography (CT) andwas adapted to be
used at magnetic resonance (MR) imaging. Pathologic re-
sponse was assessed as either good or very good. Sensitivity,
specificity, and predictive value of RECIST and Choi criteria
were calculated with pathologic response as the reference
standard and were reported with 95% confidence intervals.
Results: For 28 patients without synovial sarcomas, sensitivity of
RECIST versus adapted Choi criteria was 32.0% versus
88.0% for good response and 41.2% versus 82.4% for very
good response, respectively; specificity for pathologic re-
sponse was 100% versus 100% for not a good response and
90.9% versus 27.3% for not a very good response, respec-
tively. In synovial sarcoma, the nontreatment-related neo-
plastic cystic component of the tumor was a major obstacle
for both RECIST and Choi criteria.
Conclusion: In STS treated with chemotherapy and radiation therapy, tu-
mor size may be insufficient to render actual tumor response.
Tumor attenuation at CT or tumor contrast material enhance-
ment at MR imaging may complement tumor size, thus making
Choi criteria more predictive of pathologic response.
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There is much debate today about tu-mor response criteria in solid tu-mors. FromKarnofsky’s attempts to
codify response in lung cancer to themost
recent Response Evaluation Criteria in
Solid Tumors (RECIST) guidelines, tumor
size has been virtually the only criterion
used (1–5). There has always been de-
bate about these criteria, because it often
has been difficult to correlate response
and survival in advanced solid tumors.
The introduction of the newestmolecular-
targeted therapies has fostered further
discussion (6–15). For example, patterns
of tumor response of gastrointestinal
stromal tumors (GISTs) being treated
with imatinib are peculiar (16–22). In a
proportion of patients, there is no de-
crease in tumor size, despite the appear-
ance of hypoattenuation within the le-
sions at computed tomography (CT). So,
new criteria have been recently proposed
for GISTs and incorporate tumor attenu-
ation in addition to tumor size (11). These
criteria have been demonstrated to cor-
relate with patient outcomes better than
RECIST criteria.Molecular-targeted ther-
apies are not the only example of the lim-
itations of RECIST criteria. With regard
to the sarcomas, it has been long appre-
ciated that osteosarcomas may have a
dramatic pathologic responsewithout any
decrease in size (23–25). Recently, patho-
logic responses without any decrease in
size were reported in myxoid liposarco-
mas being treated with a new agent, tra-
bectedin (26).
This prompted us to compare ra-
diologic response as defined according
to both RECIST and the new Choi cri-
teria recently proposed for GISTs with
pathologic response in high-grade
soft-tissue sarcomas (STSs) treated
with preoperative chemotherapy and
radiation therapy (hereafter, chemo-
radiation therapy).
Materials and Methods
The institutional ethical committee ap-
proved the trial in which all patients of
this study were entered. Signed in-
formed consent was obtained for all pa-
tients.
Patients
From April 2002 to May 2006, 325 pa-
tients in Italy and Spain were enrolled in a
prospective randomized study on preop-
erative chemoradiation therapy in local-
ized STS. All patients who presented at
the National Cancer Institute, Milan, It-
aly, with localized, primary, naive, and
high-risk (high-grade, deep, size  5 cm)
STSs of the extremities or the superficial
trunk were offered enrollment in that
trial. Among 95 patients enrolled in the
study by the National Cancer Institute, we
retrospectively identified 37 patients (21
men, 16 women; mean age, 44.2 years)
who could be fully evaluated for both ra-
diologic and pathologic tumor response.
We included in the analysis only patients
with measurable disease evaluated prior
to and after treatment at the National
Cancer Institute by using the same tech-
nique (magnetic resonance [MR] imaging
or CT scanning) and the same device.We
excluded from the analysis 28 patients
who had no measurable disease at the
time of study entry, as well as another 30
patients because their pre- and posttreat-
ment radiologic assessments were not
comparable (different techniques or mo-
dalities used).
In all these patients, radiologic re-
sponse was recorded according to both
RECIST and Choi criteria. We then com-
pared RECIST with Choi criteria and used
pathologic response as a reference stan-
dard.
In all cases, the histologic type and
French National Federation of Cancer
Centres grade were assessed by using
biopsy results obtained before treat-
ment. Before surgery, patients received
three cycles of epirubicin (Farmorubi-
cina; Pfizer Italia, Nerviano, Italy) (120
mg per square meter of body surface)
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Advances in Knowledge
 Choi criteria, which are based on
changes in tumor size and attenu-
ation after contrast material ad-
ministration at CT, can be applied
to MR imaging data, assuming
that changes in contrast enhance-
ment on subtracted contrast-en-
hanced T1-weighted MR images
parallel changes in attenuation on
CT images, both being markers of
tumor vascularization.
 In all patients without synovial
sarcomas, the sensitivity of Re-
sponse Evaluation Criteria in
Solid Tumors (RECIST) versus
that of adapted Choi criteria was
32.0% (eight of 25) versus 88.0%
(22 of 25) when the reference
standard was a pathologic good
response and 41.2% (seven of 17)
versus 82.4% (14 of 17) when the
reference standard was a patho-
logic very good response.
 The specificity for pathologic re-
sponse of RECIST versus that of
adapted Choi criteria was 100%
(three of three) versus 100%
(three of three) for not a good
response and 90.9% (10 of 11)
versus 27.3% (three of 11) for not
a very good response.
Implication for Patient Care
 This study provides preliminary
evidence that tumor attenuation
at contrast-enhanced CT or tumor
contrast enhancement at MR im-
aging may complement the use of
tumor size, thus making Choi cri-
teria more predictive of patho-
logic response than only the di-
mensional criteria as defined ac-
cording to RECIST guidelines.
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plus ifosfamide (Holoxan; Baxter Oncol-
ogy, Halle Ku¨nsebeck, Germany)
(9000 mg per square meter of body
surface) for each course. Concomitant
radiation therapy was added at the
discretion of the multidisciplinary
team. The mean administered dose
was 50 Gy. Surgery was performed
within 4–6 weeks after the end of the
preoperative treatment.
MR Imaging and CT Techniques
In all cases, MR imaging or CT scanning
was performed before the preoperative
treatment and after chemoradiation
therapy, 1 day before surgery.
The examinations were performed,
and the images were evaluated by two
radiologists (A.M. for MR imaging and
C.M. for CT, with 15 years of experi-
ence each and with a specialization in
imaging sarcomas).
MR imagingwasperformedwith oneof
two 1.5-T systems (Magnetom Vision or
Avanto; Siemens, Erlangen, Germany) by
using similar pulse sequences (Table 1). In
all cases, standard unenhanced T2-
weighted TSE and T1-weighted TSE
(section thickness, 5 mm) sequences
were followed by a contrast-enhanced
T1-weighted TSE sequence and, in a
small subgroup (five patients) of pa-
tients, also by a dynamic contrast-
enhanced three-dimensional T1-
weighted gradient-echo sequence. The
intravenous bolus injection of 0.2
mmol per kilogram of body weight ga-
dopentetate dimeglumine (Magnevist;
Bayer-Schering, Berlin, Germany)
was started before initiation of data
acquisition (delay of 30 seconds for
contrast-enhanced T1-weighted TSE
sequence and 0 second for dynamic
contrast-enhanced three-dimensional
T1-weighted gradient-echo sequence).
The injection rate was 2 mL/sec.
Contrast-enhanced T1-weighted TSE
images and, when available, contrast-
enhanced three-dimensional T1-weighted
gradient-echo images were evaluated be-
fore and after digital subtraction by a
radiologist (A.M.). All data sets were
qualitatively and semiquantitatively
evaluated. The percentage of contrast
enhancement was assessed as follows:
On subtracted contrast-enhanced T1-
weighted images, the radiologist
(A.M.) measured the contrast en-
hancement of the tumor by manually
drawing a region of interest around the
margin of the whole lesion on sections
taken every 5 mm, thus encompassing
the entire tumor mass. All cystic and
necrotic areas were included. Muscle
was used as the reference tissue be-
cause it was always available in the
field. The contrast enhancement mea-
surements of all sections were added,
and the average contrast enhance-
ment for each lesion was calculated.
Because they were available in only
five cases, dynamic contrast-enhanced
three-dimensional T1-weighted gradi-
ent-echo images were not considered
in this analysis (although results were
in line with what was seen otherwise).
Table 1
MR Imaging Pulse Sequence Parameters for Patients with STS
Sequence Matrix
Section
Thickness
(mm)
Intersection
Gap (mm)
Repetition
Time
(msec)
Echo
Time
(msec)
Flip Angle
(degrees)
T2-weighted TSE 256 256 5 2 4730 153 . . .
T1-weighted TSE 254 384 5 2 616 11 . . .
Contrast material–enhanced
T1-weighted TSE 254 384 5 2 616 11 . . .
T1-weighted gradient echo 128 100 5 2 6.08 4.30 30
 TSE  turbo spin echo.
Table 2
Tumor Response according to RECIST and Choi Criteria
Response RECIST Criteria Choi Criteria
Complete response Disappearance of all lesions Disappearance of all lesions
No new lesions No new lesions
Partial response 30% decrease in the sum of greatest
diameters
10% decrease in the greatest maximal diameter or a15% decrease in tumor attenuation
at CT or contrast enhancement at MR imaging
No new lesions No new lesions
Stable disease Does not meet criteria for complete
response, partial response, or
progressive disease
Does not met criteria for complete response, partial response, or progressive disease
Progressive disease 20% increase in the sum of greatest
diameters
10% increase in the greatest maximal diameter and does not meet criteria for partial
response by using tumor attenuation at CT or contrast enhancement at MR imaging or
15% increase in tumor attenuation at CT or contrast enhancement at MR imaging and
does not meet the criteria for partial response by using tumor size
New lesion New lesion
New intratumoral nodule or increase in the size of existing intratumoral nodule
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Scanning was performed with a
16-section CT scanner (Somatom Sen-
sation 16; Siemens Healthcare, Forch-
heim, Germany), and images were re-
constructed with a 5-mm section
thickness and a 5-mm reconstruction
increment. A biphasic scanning tech-
nique was performed with scanning
delays of 20 and 60 seconds for arte-
rial and portal phases, respectively,
after intravenous injection of 130 mL
of contrast medium (Iopamidol 370;
Bracco, Milan, Italy) at a rate of 4
mL/sec. A workstation (Syngo Multi-
Modality Workplace or Leonardo; Sie-
mens Healthcare) was used for post-
processing. A radiologist (C.M.) mea-
sured CT attenuation values of the
tumor lesion (in Hounsfield units) on
CT images obtained during the portal
venous phase. Two-dimensional re-
gions of interest of the entire lesion
were drawn, and all axial sections en-
compassing the lesion were included.
To accurately define the lesion, a radi-
ologist (C.M.) edited manually the
contours of the regions of interest on
each axial section. The volume of in-
terest, covering the whole lesion, was
defined as the sum of all the two-
dimensional regions of interest. Both
cystic and necrotic areas were in-
cluded. Software calculated semiquan-
titatively the mean tumor attenuation
(in Hounsfield units) defined as the av-
erage of all the pixels enclosed in the
volume of interest.
The radiologists (A.M. and C.M.) ret-
rospectively reviewed all MR and CT im-
ages without any knowledge of histologic
responses. The percentage of change in
mean tumor attenuation or contrast en-
hancement before and after treatment
was computed for each lesion.
Tumor response was evaluated ac-
cording to RECIST and Choi criteria as
defined for GISTs and adapted for MR im-
aging (Table 2) (5,16). Therefore, accord-
ing to adapted Choi criteria, the definition
of a radiologic response was the presence
of at least a 10% decrease in tumor size or
at least a 15% decrease in tumor attenua-
tion on contrast-enhanced CT images or in
contrast enhancement on MR images.
Pathologic Assessment of Surgical
Specimen
All surgical specimens were sampled
consistently (27). The neoplasm was
mapped on its largest section, taking
about a sample per 1 cm. In addition,
all the macroscopically different areas
(ie, solid, necrotic) were described
and separately sampled. The result re-
flected the average mapping of the
whole tumor mass. When the lesion
was predominantly cystic, the diame-
ters of the cystic and solid areas were
measured and reported in the gross
description, and samples were taken
from the cystic wall. The following
characteristics of the treated tumor
mass were assessed by two patholo-
gists (P.C. and M.B., with, respec-
tively, 15 and 6 years of experience
and both devoted to sarcomas): (a)
percentage of residual viable tumor
and (b) percentages of necrosis, hem-
orrhage, sclerosis, sclerohyalinosis, fi-
brohistiocytic reaction with hemosid-
erin, myxoid component, and cystic
component.
Pathologic Assessment of Response
We codified the pathologic response
on the basis of the percentage of resid-
ual viable tumor, if at least 10% of the
mass demonstrated treatment-related
changes, like sclerohyalinosis or fibro-
histiocytic reaction with hemosiderin,
because these features are usually not
present at baseline in a high-grade STS.
We considered two different cutoffs,
which were selected prior to the eval-
uation of the radiologic data: good re-
sponse consisted of less than 50% re-
sidual viable tumor, and very good
response consisted of less than 10%
residual viable tumor.
If both the above-mentioned criteria
were not met (ie,10% of the mass had
changes known to be treatment-related
and/or there was 50% residual viable
tumor for a good response or 10%
residual viable tumor for a very good
response), the case was classified as a
Table 3
Comparison between Radiologic and Pathologic Response in Patients with STS
Criteria Radiologic Assessment
Pathologic Good
Response
Pathologic Very Good
Response
RECIST
Progressive disease 3/28 (10.7) 2.3, 28.2 3/3 (100) 29.2, 100 2/3 (66.7) 9.4, 99.2
Stable disease 17/28 (60.7) 40.6, 78.5 14/17 (82.4) 56.6, 96.2 6/17 (35.3) 14.2, 61.7
Partial response 8/28 (28.6) 13.2, 48.7 8/8 (100) 63.1, 100 7/8 (87.5) 47.3, 99.7
Choi
Progressive disease 0/28 (0) 0, 12.3 0 0
Stable disease 6/28 (21.4) 8.3, 41 3/6 (50.0) 11.8, 88.2 0/6 (0) 0, 45.9
Partial response 22/28 (78.6) 59, 91.7 22/22 (100) 84.6, 100 14/22 (63.6) 40.7, 82.8
Note.—Data are numbers of patients, with percentages in parentheses and 95% confidence intervals in brackets.
Table 4
Comparison between Radiologic Partial Response and Pathologic Response in
Patients with STS
Response Pathologic Assessment RECIST Partial Response Choi Partial Response
Good response 25/28 (89.3) 71.8, 97.7 8/25 (32.0) 14.9, 53.5 22/25 (88.0) 68.8, 97.5
Not a good response 3/28 (10.7) 2.3, 28.2 0 0
Very good response 17/28 (60.7) 40.6, 68.5 7/17 (41.2) 18.4, 67.1 14/17 (82.4) 56.6, 96.2
Not a very good response 11/28 (39.3) 21.5, 59.4 1/11 (9.1) 0.2, 41.3 8/11 (72.7) 39, 94
Note.—Data are numbers of patients, with percentages in parentheses and 95% confidence intervals in brackets.
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nonresponder (not a good response, not
a very good response).
Definition of Sensitivity and Specificity of
RECIST and Choi Criteria
We evaluated the diagnostic perfor-
mance of RECIST and adapted Choi
radiologic criteria. Sensitivity, speci-
ficity, and predictive value of RECIST
and Choi criteria were calculated with
two different pathologic response lev-
els as the reference standard and were
reported with their 95% confidence
intervals. We defined the sensitivity
for a response to be the proportion of
patients with a given radiologic re-
sponse among patients with an actual
pathologic response. We defined spec-
ificity for a lack of response as the
proportion of patients with no radio-
logic response among patients without
evidence of any pathologic response.
We considered the predictive value of
a response (positive predictive value:
probability of a pathologic response in
a patient with radiologic evidence of
response) and of a lack of response
(negative predictive value: probability
of no pathologic response in a patient
without radiologic evidence of
response) according to both RECIST
and adapted Choi criteria. In view of
the preliminary nature of the data,
no formal statistical comparison be-
tween specificity and sensitivity of
the two radiologic criteria was per-
formed.
Tumor response was dichotom-
ized as responders versus nonrespond-
ers.
Results
Enrolled Patients
Patient characteristics of the study popu-
lation are listed in Table E1 (http:
//radiology.rsnajnls.org/cgi/content/full
/2512081403/DC1). Thirty-four patients
were evaluated with MR imaging, and
three were evaluated with CT scan-
ning.
The following analysis refers to all
patients with STSs (28 patients), ex-
cept those with a diagnosis of synovial
sarcoma who were separately ana-
lyzed.
MR Imaging and CT Findings
According to RECIST criteria (Table E1,
http://radiology.rsnajnls.org/cgi/content
/full/2512081403/DC1), 28% (eight of 28)
of patients had a partial response, 61% (17
of 28) had stable disease, and11%(threeof
28) had progressive disease. According to
adapted Choi criteria, 79% (22 of 28) of
patients had a partial response, 21% (six of
28) had stable disease, and none had pro-
gressive disease.
Pathologic Findings
Of28cases, a good responsewaspresent in
25 (89%) cases, and a very good response
was present in 15 (54%) cases. In all these
cases, therewasmore than 10% sclerohya-
Figure 1
Figure 1: A, Axial T2-weighted TSE, B, T1-weighted TSE,C, contrast-enhanced (ce) T1-weighted TSE, andD, subtracted (Sub) contrast-enhanced T1-weighted TSE
MR images in 39-year-old man with pleomorphic sarcoma of posterior compartment of the thigh with heterogeneous appearance before treatment (Pre).C,Diffuse en-
hancement is noted surrounding well-circumscribed areas of low signal intensity, which are consistent with necrotic spaces. After treatment (Post), E, axial T2-weighted
TSE, F, T1-weighted TSE,G, contrast-enhanced T1-weighted TSE, andH, subtracted contrast-enhanced T1-weighted TSE MR images show a marked increase in size
(more than 85% increase in maximum diameter, which is progressive disease according to RECIST criteria), with homogeneous hyperintensity on T2-weighted image
and evident decrease in tumor contrast enhancement (decrease of 89%, which is partial response according to adapted Choi criteria). These images show a fluid-fluid
level due to blood products within the lesion. I, Posttreatment histopathologic finding (Path) (hematoxylin-eosin stain; magnification,200) shows signs of response to
chemotherapy. The residual mass is composed of a pseudocystic cavity full of necrotic debris and hemorrhagic fluid, surrounded by a wall formed by less than 5% resid-
ual viable tumor cells in the presence of more than 10% sclerohyalinosis and fibrohistiocytic reaction. This is a very good pathologic response.
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linosis and/or fibrohistiocytic reaction with
hemosiderin.
Correlation between Pathologic and
Radiologic Findings
The comparison between radiologic de-
termination of response and pathologic re-
sponse is summarized in Tables 3 and 4.
Examples are shown in Figures 1 and 2.
The accuracy of both RECIST and
adapted Choi criteria is summarized in
Table 5. Of 25 patients with a pathologic
good response, only eight had a partial
response according to RECIST criteria,
while 22 were partially responsive ac-
cording to adapted Choi criteria. Of 17
patients with a pathologic very good re-
sponse, a response was seen in seven
patients according to RECIST criteria
and in 14 patients according to adapted
Choi criteria. The sensitivity of RECIST
criteria was less than 50% for both good
response (32.0% [eight of 25]) and very
good response (41.2% [seven of 17]),
while the sensitivity of adapted Choi cri-
teria was more than 80% for both
groups (88.0% [22 of 25] for good re-
sponse and 82.4% [14 of 17] for very
good response). The three cases with-
out a pathologic good response were all
found to be nonresponders according to
both RECIST and adapted Choi criteria.
The specificity was 100% for both crite-
ria when a good response was selected
as the reference standard. If a very good
response was considered the reference
standard, the specificity was 90.9% (10
of 11) for RECIST and 27.3% (three of
11) for adapted Choi criteria.
The predictive value of a nonre-
sponder (Table 5) according to RECIST
criteria was 15.0% (three of 20) with a
pathologic good response as a reference
standard and 60.0% (12 of 20) with a
pathologic very good response as a ref-
erence standard. Of 20 patients without
a response according to RECIST crite-
ria, there were only three patients in
whom pathologic evidence of a good re-
sponse was not found. On the contrary,
when a pathologic very good response
was selected as a criterion, a pathologic
response was not found in 12 of 20
cases according to RECIST criteria. The
positive predictive value of a response
according to either RECIST or adapted
Choi criteria was 100% if we considered
a pathologic good response (eight of
eight for RECIST criteria and 22 of 22
for Choi criteria) as the criterion, while
positive predictive value was 87.5%
(seven of eight) and 63.6% (14 of 22),
respectively, for RECIST and adapted
Choi criteria if we considered a patho-
logic very good response as the crite-
rion.
Synovial Sarcoma
Of nine synovial sarcomas, five patients
had partial response and four had stable
disease according to RECIST criteria.
According to adapted Choi criteria,
there were seven partial responses and
two with stable disease. Evidence of a
response at pathologic examination was
Figure 2
Figure 2: A, Axial T2-weighted TSE, B, T1-weighted TSE,C, contrast-enhanced (ce) T1-weighted TSE, andD, subtracted (Sub) contrast-enhanced T1-weighted TSE
MR images in 69-year-old man with pleomorphic sarcoma of the thigh before treatment (Pre). The mass is heterogeneous in appearance.C,Diffuse enhancement is
noted surrounding well-circumscribed areas of low signal intensity, consistent with necrotic spaces. After treatment (Post), E, T2-weighted TSE, F, T1-weighted TSE,
G, contrast-enhanced T1-weighted TSE, andH, subtracted contrast-enhanced T1-weighted TSE MR images show an increase in maximum diameter (20%, which is
stable disease according to RECIST criteria), with heterogeneous hyperintensity on T2-weighted image and consistent decrease in tumor contrast enhancement (de-
crease of 51%, which is partial response according to adapted Choi criteria). These images show hyperintensity on T1-weighted images due to presence of blood prod-
ucts within the lesion. I,Histopathologic finding (Path) (hematoxylin-eosin stain; magnification,200) after chemoradiation therapy shows evidence of pathologic re-
sponse to treatment, with only a few isolated residual viable tumor cells (arrow) within diffuse sclerohyaline tissue (15% residual viable tumor cells and more than 10%
sclerohyalinosis, which is a good response).
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found in two cases, and both were very
good responses. In these two patients,
there was a partial response according
to adapted Choi and RECIST criteria. In
all cases of partial response according
to RECIST and adapted Choi criteria
without a pathologic response, there
was no tissue response (ie, no contrast
enhancement decrease) in the solid
component of the tumor (Fig 3).
Discussion
The response of solid tumors to medical
therapies has long been evaluated on
the basis of tumor size. In spite of the
effort made by the radiologists to im-
prove response assessment with new
techniques (28,29), the standard tumor
response criteria in clinical trials are
still based only on tumor size. Several
criteria have been used (eg, World
Health Organization, Eastern Coopera-
tive Oncology Group, Southwest Oncol-
ogy Group, RECIST) (1–5). By and
large, the criteria are equivalent, inas-
much as a 50% reduction in an area
(World Health Organization, Eastern
Cooperative Oncology Group, South-
west Oncology Group) is tantamount to
a 30% reduction in a single diameter
(RECIST). More recently, the appropri-
ateness of such criteria has been chal-
lenged with regard to the tumor re-
sponse of GISTs to imatinib (16–22).
This has been observed also in other
tumors (30–32). In GISTs, new re-
sponse assessment criteria proposed by
Haesun Choi, incorporating not only tu-
mor size but also changes in tumor at-
tenuation after contrast enhancement
on CT scans, were shown to predict
prognosis better than RECIST criteria.
It has always been difficult to dem-
onstrate partial response to therapy at
imaging in many advanced solid tumors
(10–15). Molecular-targeted therapies
give rise to a different antitumor effect
and highlight the limitations of size cri-
teria in the assessment of tumor re-
sponse to these agents. These problems
in tumor response assessment may ap-
ply also to cytotoxic chemotherapy. This
prompted us to apply Choi criteria in
this study. Indeed, these preliminary
data show that this may be worthwhile.
In our study of localized, high-risk
STSs treated with preoperative chemora-
diation therapy, radiologic changes in tu-
mor size as defined according to RECIST
criteria were less sensitive than those
of adapted Choi criteria in predicting
pathologic tumor response; sensitivity
was 32.0% versus 88.0% for good re-
sponse, respectively, and 41.2% ver-
sus 82.4% for very good response, re-
spectively. With respect to specificity,
adapted Choi criteria tended to over-
rate the response only if we used the
criterion of less than 10% residual vi-
able tumor cells (ie, a very good re-
sponse) as the reference standard for
Table 5
Diagnostic Performance of Imaging Criteria in Identifying Treatment Response in Patients with STS
A: Sensitivity for Response
Response
Sensitivity (%)
Partial Response according to
RECIST Criteria 95% Confidence Interval
Partial Response according to
Choi Criteria 95% Confidence Interval
Pathologic good response (n 25 ) 32 (8/25) 14.9, 53.5 88 (22/25) 68.8, 97.5
Pathologic very good response (n 17) 41.2 (7/17) 18.4, 67.1 82.4 (14/17) 56.6, 96.2
B: Specificity for No Response
Specificity (%)
Response
No Response according to
RECIST Criteria
95% Confidence
Interval
No Response according to
Choi Criteria 95% Confidence Interval
Pathologic not a good response (n 3) 100 (3/3) 29.2, 100 100 (3/3) 29.2, 100
Pathologic not a very good response (n 11) 90.9 (10/11) 58.7, 99.8 27.3 (3/11) 6, 61
C: Predictive Value of Radiologic Response
Positive Predictive Value (%)
Response Pathologic Good Response
95% Confidence
Interval
Pathologic Very Good
Response 95% Confidence Interval
Partial response according to RECIST criteria
(n  8) 100 (8/8) 63.1, 100 87.5 (7/8) 47.3, 99.7
Partial response according to Choi criteria (n 22) 100 (22/22) 84.6, 100 63.6 (14/22) 40.7, 82.8
D: Predictive Value of Radiologic No Response
Negative Predictive Value (%)
Response
Pathologic Not a Good
Response
95% Confidence
Interval
Pathologic Not a Very Good
Response 95% Confidence Interval
No response according to RECIST criteria (n 20) 15 (3/20) 3.2, 37.9 60 (12/20) 36.1, 80.9
No response according to Choi criteria (n 6) 50 (3/6) 11.8, 88.2 100 (6/6) 54.1, 100
Note.—Numbers in parentheses were used to calculate percentages.
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pathologic response, while there was a
full correspondence if the reference
standard for pathologic response was
considered the presence of less than
50% residual viable cells (ie, a good
response).
Most patients in our study were
evaluated with MR imaging, which is
often used to study STS of the extremi-
ties. We therefore had to adapt Choi
criteria to MR imaging. To this end, we
selected changes in contrast enhance-
ment on subtracted contrast-enhanced
T1-weighted images to parallel hypoat-
tenuation on postcontrast CT scans,
both being markers of tumor vascular-
ization.
In GISTs, Choi criteria were vali-
dated by analyzing progression-free sur-
vival as a criterion (11). Unfortunately,
this was not feasible in our study. We
could not take any outcome measure as
a criterion, because it has not yet been
demonstrated if adjuvant chemotherapy
has any prognostic effect in STS (28,33–
37). We therefore chose to analyze
pathologic response as the reference
standard. To this end, we noted the per-
centage of residual viable tumor and
chose two arbitrary cutoffs (10% for
very good response and 50% for good
response), provided we could find alter-
ations that were definitively related to
posttreatment changes. Necrosis and
hemorrhage were not considered be-
cause they can be present at baseline in
high-grade STSs.
Our data suggest that RECIST crite-
ria for treatment response have a lower
sensitivity for pathologic response than
adapted Choi criteria. This reflects the
fact that in some patients, responses to
treatment were not accompanied by de-
crease in tumor size. In some respond-
ing patients, tumor size did in fact in-
crease. This closely parallels what is
seen in GISTs being treated with molec-
ular-targeted therapies. If we use patho-
logically determined very good response
(10% residual viable tumor) as the
reference standard, adapted Choi crite-
ria show low specificity (ie, a lack of
pathologic major response was pre-
dicted less by using adapted Choi crite-
ria). In only 63.6% (14 of 22) of patients
with evidence of a response according
to adapted Choi criteria, there was a
major response to therapy (very good
response) according to pathologic find-
ings.
The identification of a treatment re-
sponse at CT or MR imaging in patients
with synovial sarcoma poses additional
challenges. Synovial sarcoma masses
may commonly demonstrate a non-
treatment-related cystic truly neoplas-
tic component. On images, it may be
impossible to distinguish these cystic ar-
eas from tumor response. The cystic ar-
eas in synovial sarcoma are histologi-
cally different from necrosis because
these cystic areas are lined by intact
Figure 3
Figure 3: MR images, surgical specimen (Surg), and histopathologic finding (Path) in 22-year-old woman with synovial sarcoma of the thigh with cystic components.
A,Axial T2-weighted TSE,B, coronal T1-weighted TSE, andC, coronal contrast-enhanced (ce) T1-weighted TSE MR images at baseline (Pre).D, E,Subtracted (Sub)
contrast-enhanced T1-weighted TSE MR images. F,Axial T2-weighted TSE,G, coronal T1-weighted TSE, andH, coronal contrast-enhanced T1-weighted TSE MR im-
ages of lesion after treatment (Post). I, L,Subtracted (Sub) contrast-enhanced T1-weighted TSE MR images.M, Posttreatment surgical specimen with cystic component
erroneously interpretable as necrotic area.N,Histopathologic finding (hematoxylin-eosin stain; magnification,200). After treatment, there is no change in size (stable
disease according to RECIST criteria), but there is a 20% decrease in contrast enhancement when calculated on the whole lesion (D and I) because of an increase of cystic
component (partial response according to Choi criteria). Contrast enhancement is increased (30%) if only the solid part is considered (E and L).M, The solid part of the
tumor located beside the true cystic area full of serous fluid is composed of 90% residual viable tumor cells without posttreatment alterations.
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neoplastic cells. In our study, a cystic
component at baseline was observed in
four of nine patients with synovial sar-
coma. After therapy, these components
remained stable or even increased in
size. As they are hypovascular, the ra-
diologist may interpret an increase in
cystic area size as a response to ther-
apy. However, the pathologist can iden-
tify the active tumor cells in the walls of
the cysts and readily recognize the lack
of response to therapy. For these rea-
sons, Choi criteria as currently defined
do not seem to be appropriate for the
assessment of the response of a synovial
sarcoma, which must be further evalu-
ated.
Our study had a number of limita-
tions. It was a retrospective study (al-
though within a prospective trial), per-
formed on a small series of cases, which
does not allow a good precision of re-
sults, as shown by wide confidence in-
tervals of estimates. Second, we could
not correlate response with overall sur-
vival or progression-free survival. Third,
we arbitrarily chose pathologic response
as a criterion to assess the value of
adapted Choi versus RECIST criteria.
Even the threshold for pathologic re-
sponse was arbitrarily chosen because
of the lack of standard criteria for re-
sponse evaluation in STSs. However,
this should be viewed as a hypothesis-
generating study. Prospective correla-
tive analyses with the outcome as a cri-
terion are needed. In regard to STS,
when constructing new criteria, the
complex architecture of some histologic
types, such as synovial sarcoma, should
be considered.
In conclusion, our study suggests
that even in solid tumors being treated
with cytotoxic chemotherapy, the crite-
rion of tumor size alone may be insuffi-
cient. Tumor attenuation at CT or tu-
mor contrast enhancement at MR imag-
ing may complement tumor size as a
criterion.
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